will disease. I trials on Thanks, our an PRECISION-HDX and Paul. Today, with clinical treatment of PRECISION-HDX begin update Huntington's for the
have COVID-XX focused the and safety the teams, pandemic, During ensuring study patients of keenly on investigators. we our remained
cohorts successful While continued both restrictions. trial-type for clinical Progress clinical needed facing to the XX-milligram trials or have have complete we are patients continued to has new identifying studies. both the at been investigators patients and advance, continued and
treatment as our anticipate as efficiently we well quarter studies trials SNPX prioritization; beginning we our because At XXXX. possible, cohorts disease-modifying enroll in both of studies safely data patients on our of and the these from as trials the of dosing clinical open-label are studies, we track the sites. the pandemic hopeful to based and the the time and that we now were PRECISION-HD able the locations infrequent of regimen authorities, While for by to our trial as the being on from share and extension working update, of SNPX last keep of all could first data health
continue clinical of or submission SNP trial SNPX. patients beginning mutant this fourth is While helpful third clinical which huntingtin quarter the been that for been a HD why in certainly expanding application, critical selectively We impact allele-selective in development any we achieving of development, which CTA, coronavirus to to to with commitment our lowering the long-term ongoing the therapeutic will clinical occur program of a the expected our with be unavoidable. of believe are with Preparations is has benefit the X, towards HD, XXXX. has of
programs well as as leveraged incorporates both designing from first have learnings candidate validation, a from our when in which our platform the of terms screening, target clinical our in advancement novel HD our We advancements platform. in vivo and compound, PRISM chemistry SNPX identification
we We a and for to compound, were the phased SNPX than studies was only time a identified over feasibility enrollment. developing the years level, Asuragen development to enable and several methods significantly next measurement past each phasing we entered eligible proved our diagnostic companion for collaboration to and of SNPX for line When patients of be more can Neurology have advances study, journey, successfully successfully the through we for a Since published identifying SNPX that identify the this be the possible, a our Taking relevant Beyond last started evolved commercialization told biomarkers. development. SNPs efficiently. for or have programs. phasing with not of this fluid which prospective burdensome patients targeting potential recently the year our in lead process observational of but was phasing and a we Genetics, confirm our we approach SNPX we in have into enough appropriate in SNP in to not patients too therapeutic and then called SNP clearly accomplished with practical
enable patient scalable SNPX. Just our recently, we expanded this agreement in their selection to technology trial use us upcoming clinical for for to
also HD has together why the has with healthy XX% is of address the huntingtin To we or own, importance the XX% the patients nervous fact population. have biological there using our to conversations and patient allele sure role congress of huntingtin, selectivity significant the half approximately Huntington's minimizing in Disease community. around potential so this. wild-type confirmed our of the believe SNPX Huntingon's population matters, addresses data to an with both a HDSA, only approximately as up given have Society June effects as who system HD understanding with Huntington’s I'm any the HD systemically. America, of its and to on the on samples Today, of noticed those it in broaden to program we the have level the This virtual functions, SNPX the remind you supporting not SNPX growing The you the listened of reach the portion population central observational this program HD in Our from patients continues wild-type disease study. SNPX the disease in does of grow, and protein many on as and critical potential we our programs, into observation population. of plays recognition
that to told been also would it HD have possible patients. never in of huntingtin wild-type the We CSF be measure
this impact work our data to have for complete We huntingtin is made turned focus as and in that treatments on understand updated strive this we our progress. to of forward potential and keeping have the to look wild-type critical We you time readouts. scientific it to believe challenge
turning for dementia or diseases FTD; of our genetic sporadic Now CXorfXX or genetic are the frequent strong of devastating genetic CXorfXX lateral amyotrophic familial front both a diseases. of sclerosis these risk most two the the also neurodegenerative factor targeting are focus temporal ALS program, in that forms and cause forms fatal. mutations to of
the Our central and of silence the which CXorfXX-targeting selectively formation compound drives hexanucleotide toxic in the is repeat-containing potently transcripts, and RNA nervous system. designed proteins to
agreed and striking other had is of in repeats with plan associated share well in a clinical transgenic We this and to developments measure effects the stakeholders dipeptide levels this design regulatory upon and target CXorfXX ability of both The in rapidly biomarker durable in candidate engagement include FTD more ALS once and in relatively details to patients the clinical both later animal while of on both protein for Our the to FTD repeat-containing our We will us clinical CSF knockdown leaving the authorities. opportunity with intention the hope details efficacy transcripts including assess peptides, to year signs neurodegeneration the are intact. in with the key to advance ALS as patients trial afford potent of trial critical biomarkers models indications. as clinic.
with research of from our program, continue differentiated to upcoming advantage Similar innovations to of We year. to CX expect that be other compound will takes quarter the our in PRISM this platform our have to our program therapeutic webcast. fourth from the to CTA this Dr. in detail SNPX potential program led a more Rhodes Ken approaches. submit during discuss this highly
Gaiero David a that over it review for with I'll of turn to So financials. our
